Exosome Diagnostics said Tuesday that it has closed $27 million in Series B financing. New investors QIAGEN and Arcus Ventures led the round with participation from Tiger Partners, CD Ventures, Monashee Capital, NGN Capital and Forbion Capital Partners. Leerink Swann served as financial advisor and placement agent to Exosome on the transaction. In conjunction with the funding, Dr. Steven Soignet, general partner at Arcus Ventures, has been added to Exosome’s board of directors. Exosome is a developer of molecular diagnostic tests.